| Synthetic - Part 8

Here’s What Glycobiologists Are Doing For Cancer Research

May 5, 2021May 17, 2021 by Staff

Glycobiology crosses many fields including chemistry, biology, medicine, and materials science. Broadly speaking, glycobiology is the study of the structure, biosynthesis and biology of glycans (carbohydrates). All cells and many proteins are covered with a dense and complex array of covalently attached sugar chains (called oligosaccharides or glycans). The biological roles of these glycans become particularly important … Read more

This Startup Targets Transfer RNA (tRNA) Mechanisms

May 3, 2021May 3, 2021 by Simons Chase

Shape Therapeutics (ShapeTX) is developing a new generation of gene therapies for some of the most daunting genetic. Its RNA technologies leverage machinery already present in human cells to correct genetic mutations, while avoiding immunogenicity and DNA damage. This process aims provide safer treatments that work with the body, not against it. Here is how … Read more

The Link Between Evolution And Immunotherapy

April 30, 2021April 30, 2021 by Staff

According to Dr. Francis Collins, evolutionary studies – comparing the development of these systems across animals and organisms – are now leading to unexpected biological discoveries and promising possibilities for preventing and treating human disease. While there are many evolutionary questions to ask, Brenda Bass, a distinguished biochemist at University of Utah, Salt Lake City, … Read more

DARPA Dive: Nucleic acids On-demand Worldwide (NOW)

April 29, 2021April 29, 2021 by Staff

The Defense Advanced Research Projects Agency (DARPA), established in 1958, is an agency within the Department of Defense (DOD) responsible for catalyzing the development of technologies that maintain and advance the capabilities and technical superiority of the U.S. military. In short, it’s the way the U.S. military tries to prevent technical surprise. The Nucleic acids … Read more

IPO: Recursion Pharmaceuticals Leverages Therapeutics Discovery With Machine Learning

April 27, 2021April 27, 2021 by Staff

Recursion Pharmaceuticals Inc. uses machine learning to hunt for new therapies. The company raised $436 million in an upsized initial public offering priced at the top of a marketed range. Last week , the Salt Lake City-based company sold about 24 million shares for $18 each. Recursion is among a crop of new startups called … Read more

Proteogenomics And Head and Neck Cancer

April 27, 2021April 27, 2021 by Staff

Proteogenomic has the potential to match cancer patients with an effective therapy for their particular cancer. A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment. The research led by Baylor College of Medicine, Johns Hopkins University and the National Cancer … Read more

How Oncology Is Migrating Towards Proteogenomics

April 20, 2021April 20, 2021 by Staff

Where is cancer research headed in the next decade? Scientists and oncologists at the National Cancer Institute share their thoughts on proteogenomics. Oncology has experienced more constant change in the last 30 years than from the late 20th century to the time cancer was first identified in 440 B.C. The rapid pace of innovation in … Read more

Chipmaker NVIDIA Wades Into Medical Industry

April 13, 2021April 27, 2021 by Simons Chase

The PC gaming market inflected upwards in 1999, sparking the geometric growth of parallel processing computer chips designed to optimize gaming. More recently, GPU deep learning ignited modern AI — the next era of computing — with the GPU acting as the brain of computers, robots, and self-driving cars that can perceive and understand the … Read more

IBM’s Quantum Computing Platform To Integrate With Cleveland Clinic

March 31, 2021March 31, 2021 by Staff

Synthetic biology starts and ends with data, and it’s no secret that the human immune system is migrating to the cloud. Cleveland Clinic and IBM have announced a planned 10-year partnership to establish the Discovery Accelerator, a joint Cleveland Clinic – IBM center with the mission of fundamentally advancing the pace of discovery in healthcare and … Read more

Here Is Another PIPE & SPAC Combo In The Proteomics Space

March 22, 2021March 22, 2021 by Staff

Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition Corp III, a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors, announced in February a definitive business combination agreement. The combined company is expected to receive proceeds of approximately $350 million at the closing … Read more